Drug Discovery Research Centered on the Watarase Drug Discovery Center
First written in FY2017-Q1. 4 of 9 entries say "Restated". Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023AchievedAnnual report
「As resolved at the meeting of the Board of Directors held on 2 August 2022, the subsidiary ActivX Biosciences, Inc., one of 杏林製薬㈱'s research bases, was dissolved in March 2023.」
Following the policy and resolution to dissolve ActivX Biosciences, the dissolution was completed in March 2023. - FY2023-Q3AdvancedAnnual report
「Following the decision on a policy to dissolve ActivX Biosciences, Inc., our consolidated subsidiary, we reduced its carrying value to its recoverable amount and recognized the reduction of ¥105 million as an impairment loss under extraordinary losses.」
In connection with the policy to dissolve ActivX Biosciences, the company recognized an impairment loss of ¥105 million, and accounting procedures toward dissolution progressed. The disclosure does not state that the dissolution was completed. - FY2023-Q2AdvancedAnnual report
「At a meeting of the Board of Directors held on 2 August 2022, 杏林製薬㈱ decided to dissolve its subsidiary ActivX Biosciences, Inc., one of its research bases, by 31 March 2023, and to consolidate its research bases at the Watarase Drug Discovery Center.」
The policy to dissolve ActivX Biosciences progressed to a Board of Directors decision, and consolidation of the research bases at the Watarase Drug Discovery Center by 31 March 2023 was announced. - FY2023-Q1ReframedAnnual report
「杏林製薬㈱ decided on a policy to dissolve its consolidated subsidiary ActivX Biosciences, Inc. by 31 March 2023.」
Regarding the in-house drug discovery structure, including collaboration between the Watarase Drug Discovery Center and ActivX, a policy to dissolve ActivX Biosciences was announced, changing the basis of the structure. - FY2019RestatedAnnual report
「In-house drug discovery through collaboration between the Watarase Drug Discovery Center and ActivX」
We continue in-house drug discovery based on collaboration between the Watarase Drug Discovery Center and ActivX. - FY2017RestatedAnnual report
「In in-house drug discovery, activities at the Watarase Drug Discovery Center, established in July 2015, got on track, and we advanced drug discovery research focused on specific disease areas, based on basic research in inflammation, immunology and infectious diseases.」
We continue disease-focused drug discovery research based at the Watarase Drug Discovery Center. - FY2017-Q3RestatedAnnual report
「In in-house drug discovery, activities at the Watarase Drug Discovery Center, established in July 2015, got on track, and we advanced drug discovery research focused on specific disease areas, based on basic research in inflammation, immunology and infectious diseases.」
We continue disease-focused drug discovery research based at the Watarase Drug Discovery Center, with inflammation, immunology and infectious diseases as its foundation. - FY2017-Q2RestatedAnnual report
「In in-house drug discovery, activities at the Watarase Drug Discovery Center, established in July 2015, got on track, and we advanced drug discovery research focused on specific disease areas, based on basic research in inflammation, immunology and infectious diseases.」
We continue disease-focused drug discovery research based at the Watarase Drug Discovery Center, with inflammation, immunology and infectious diseases as its foundation. - FY2017-Q1First statedAnnual report
「In in-house drug discovery, activities at the Watarase Drug Discovery Center, established on 7 July 2015, have gained momentum, and we advanced drug discovery research focused on specific disease areas based on fundamental research fields including inflammation, immunology and infectious diseases.」
The drug discovery center established in July 2015 is operating on a stable footing and is being used to advance disease-focused research based on inflammation, immunology and infectious diseases.